Want to join the conversation?
$ENDP 2Q15 Q&A: Gary Nachman from Goldman Sachs asked on adhesive capsulitis and cellulitis, how the Phase IIb studies look like in terms of size and scope? Rajiv said, the planning is progressing well. We have not yet finally concluded on the sizing & we do expect to conclude all of those and initiate trial towards back end of this year.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.